Pub. Date : 2002 Jun
PMID : 12060061
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | AIMS: Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. We investigated the multiple-dose pharmacokinetic properties of insulin glargine to determine whether daily injections lead to the accumulation of circulating insulin levels and a corresponding decrease in blood glucose levels in patients with Type 1 diabetes. | Insulin Glargine | insulin | Homo sapiens |
| 2 | AIMS: Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. We investigated the multiple-dose pharmacokinetic properties of insulin glargine to determine whether daily injections lead to the accumulation of circulating insulin levels and a corresponding decrease in blood glucose levels in patients with Type 1 diabetes. | Insulin Glargine | insulin | Homo sapiens |
| 3 | AIMS: Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. We investigated the multiple-dose pharmacokinetic properties of insulin glargine to determine whether daily injections lead to the accumulation of circulating insulin levels and a corresponding decrease in blood glucose levels in patients with Type 1 diabetes. | Insulin Glargine | insulin | Homo sapiens |
| 4 | AIMS: Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. We investigated the multiple-dose pharmacokinetic properties of insulin glargine to determine whether daily injections lead to the accumulation of circulating insulin levels and a corresponding decrease in blood glucose levels in patients with Type 1 diabetes. | Insulin Glargine | insulin | Homo sapiens |
| 5 | Each patient"s optimal insulin glargine dose was determined during a dose-finding phase. | Insulin Glargine | insulin | Homo sapiens |
| 6 | After a washout period, patients were treated over 12 days with a constant daily dose of insulin glargine injected in the abdominal subcutaneous adipose tissue at 22:00 h, and with preprandial insulin lispro. | Insulin Glargine | insulin | Homo sapiens |
| 7 | These results indicate that the predetermined dose of insulin glargine will not need to be reduced after commencing treatment because of a risk of accumulation. | Insulin Glargine | insulin | Homo sapiens |